EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services provided preliminary approval for the transitional pass-through reimbursement scheme for the firm's proprietary Wireless Stimulation Endocardially cardiac resynchronization therapy system, according to a Tuesday Australian bourse filing.
The preliminary approval is expected to become effective in October and will be effective for three years.
The firm said it will continue to engage with the agency through the upcoming annual rulemaking and public comment process.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。